English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Pro

Presents the zaia usage as premium feature

ZAIA

Presents AI Discovery search usage as a premium feature

AI Discovery

Presents AI Discovery explain and summary usage as a premium feature

Content Analysis

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Presents the pdf analysis as premium feature

PDF Analysis

1500 Top-up

3000 Top-up

Zendy Basic

2500 Top-up

Zendy Unlimited

Presents the access of premium content as premium feature

Premium Content

It has been over a decade since Health Canada approved infliximab (Remicade®, Centocor Inc.), the first tumor necrosis factor-α (TNF-α) inhibitor, for the treatment of rheumatoid arthritis (RA). The approval of etanercept (Enbrel®, Amgen Inc.) and adalimumab (Humira®, Abbott Laboratories) followed shortly after, as well as a spectrum of other indications for this new therapeutic class. These agents not only revolutionized the treatment of immune-mediated inflammatory diseases (IMID), but also contributed to our understanding of common underlying pathologies of these clinically …

From Bedside to Bench: The Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory Diseases